Current Ratio
since 2005
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Illumina Inc., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2020 | = | ÷ | |||
| Dec 29, 2019 | = | ÷ | |||
| Dec 30, 2018 | = | ÷ | |||
| Dec 31, 2017 | = | ÷ | |||
| Jan 1, 2017 | = | ÷ | |||
| Jan 3, 2016 | = | ÷ | |||
| Dec 28, 2014 | = | ÷ | |||
| Dec 29, 2013 | = | ÷ | |||
| Dec 30, 2012 | = | ÷ | |||
| Jan 1, 2012 | = | ÷ | |||
| Jan 2, 2011 | = | ÷ | |||
| Jan 3, 2010 | = | ÷ | |||
| Dec 28, 2008 | = | ÷ | |||
| Dec 30, 2007 | = | ÷ | |||
| Dec 31, 2006 | = | ÷ | |||
| Jan 1, 2006 | = | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$ in millions
The analysis of the current assets, current liabilities, and current ratio over the observed periods reveals notable trends in liquidity management and financial stability.
- Current Assets
- There is a consistent upward trend in current assets from 80 million US dollars in early 2006 to 4,483 million US dollars at the end of 2020. The growth is steady, with significant increments especially noticeable from 2017 onwards, where the figures rise sharply from 2,318 million to nearly 4,500 million by 2020. This indicates an increasing ability to cover short-term obligations and an expanding asset base.
- Current Liabilities
- Current liabilities exhibit more volatility compared to current assets. Starting at 22 million US dollars in 2006, there is a substantial increase up to 510 million by late 2008, followed by fluctuations including a notable peak of 1,804 million in 2018. This peak might indicate a period of increased short-term borrowing or obligations. The values decline in the subsequent years but rise again in 2020. Overall, liabilities demonstrate periods of strain and adjustment.
- Current Ratio
- The current ratio, a key liquidity indicator, reflects the interplay between current assets and liabilities. It starts relatively high at 3.67 in early 2006 and experiences varied fluctuations over the years. There is a decline to 1.7 in 2008, suggesting tighter liquidity possibly due to the increased liabilities that year. From 2010 to 2013, the ratio stabilizes at relatively high levels between 3.29 and 6.5, indicating strong liquidity positions. A dip is seen again around 2014-2018, coinciding with the spikes in liabilities, lowering the ratio to as low as 2.49 in 2018. By 2020, the current ratio increases again to 3.6, signifying improvement in liquidity.
In summary, the company demonstrates overall growth in current assets, suggesting enhanced capacity to meet short-term obligations. However, fluctuations in current liabilities have intermittently pressured liquidity positions, as reflected in the variable current ratio. The recent years show a recovery in liquidity after periods of elevated short-term liabilities, indicating potentially improved financial management or operational performance.
Comparison to Competitors
Illumina Inc., current ratio, long-term trends, comparison to competitors
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | |||||||||||||
| Dec 29, 2019 | |||||||||||||
| Dec 30, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Jan 1, 2017 | |||||||||||||
| Jan 3, 2016 | |||||||||||||
| Dec 28, 2014 | |||||||||||||
| Dec 29, 2013 | |||||||||||||
| Dec 30, 2012 | |||||||||||||
| Jan 1, 2012 | |||||||||||||
| Jan 2, 2011 | |||||||||||||
| Jan 3, 2010 | |||||||||||||
| Dec 28, 2008 | |||||||||||||
| Dec 30, 2007 | |||||||||||||
| Dec 31, 2006 | |||||||||||||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc., current ratio, long-term trends, comparison to industry (health care)
| Illumina Inc. | Health Care | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).